Trials / Recruiting
RecruitingNCT07496021
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- CKD Bio Corporation · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L. lactis CKDB001 | Oral Capsule |
| DRUG | Placebo | Oral Capsule |
Timeline
- Start date
- 2026-02-23
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
- First posted
- 2026-03-27
- Last updated
- 2026-03-30
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07496021. Inclusion in this directory is not an endorsement.